Market Cap 543.44M
Revenue (ttm) 114.70M
Net Income (ttm) -56.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -49.29%
Debt to Equity Ratio 0.00
Volume 2,166,300
Avg Vol 4,058,384
Day's Range N/A - N/A
Shares Out 227.38M
Stochastic %K 76%
Beta 1.94
Analysts Strong Sell
Price Target $9.00

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercia...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 684 1300
Address:
3115 Merryfield Row, Suite 120, San Diego, United States
Finnish_boy
Finnish_boy Oct. 31 at 12:29 PM
$GOSS Statistical significance is around 17-18m!! What are the odds that 6mwd is over 20m? I can tell that exteremely high. Lets go!🤑
0 · Reply
Finnish_boy
Finnish_boy Oct. 31 at 12:29 PM
$GOSS "I don't think the investment community has fully yet picked up on that dialogue that's going on in the community." >25m home run 20-25m clinically meaningful 19m already enough for approval What will they show in February, 20m, 25m, or 30m? I like all of them.
1 · Reply
Finnish_boy
Finnish_boy Oct. 28 at 9:58 PM
0 · Reply
mdalinaqvi
mdalinaqvi Oct. 28 at 7:48 PM
$GOSS I am happy with the fact that I have done my thorough due diligence and I entrust my investment in the very capable hands of the management and the board. See you all in Feb 🙏🏻👍
0 · Reply
mdalinaqvi
mdalinaqvi Oct. 28 at 7:33 PM
$GOSS Another fun fact - Mr. Robert Roscigno, PhD (Senior Vice President of Clinical Development, Pulmonary Vascular Disease) Joined Gossamer Bio in July 2020 and has served as Senior Vice President of Clinical Development, Pulmonary Vascular Disease, since September 2024. He is the clinical lead of the Seralutinib program. Dr. Roscigno possesses over 27 years of drug development experience related to pulmonary hypertension and has extensive expertise in developing novel drug/device delivery systems (inhalation, intravenous, subcutaneous) for the pharmaceutical market. He is a co-inventor on multiple U.S. patents and has published numerous articles in scientific journals. Prior to his tenure at Gossamer Bio, Dr. Roscigno held the position of Senior Vice President of Product Development and served as the program lead for LIQ861 (YUTREPIA™) at Liquidia Corporation. He was responsible for advancing the company’s lead product from preclinical testing to NDA submission.
0 · Reply
mdalinaqvi
mdalinaqvi Oct. 28 at 7:27 PM
$GOSS Another fun fact - Mr. Bob Smith - Chief Commercial officer Mr. Smith has over 30 years of experience in pharmaceuticals, with a strong focus on PAH and rare disease. Prior to joining Gossamer, Mr. Smith was the National Sales Lead in charge of preparing for the potential launch of sotatercept for the treatment of PAH in the US at Merck & Co. Mr. Smith spearheaded two successful blockbuster PAH drug launches, OPSUMIT and UPTRAVI, which ultimately led to the purchase of Actelion by Johnson & Johnson in 2017 for $30 billion.
0 · Reply
mdalinaqvi
mdalinaqvi Oct. 28 at 7:24 PM
$GOSS Fun Fact about a Board member of Gossamer Bio - Dr. John Quisel Dr. Quisel is currently the President and CEO of Disc Medicine, a position he has held since January 2020 and during which time, the company established a multi-product portfolio of hematology programs and became a publicly-traded company. Previously, Dr. Quisel was the Executive Vice President and Chief Business Officer at Acceleron Pharma, where he spent more than thirteen years in various senior roles helping to build the company from a privately-held startup to a fully-integrated, publicly-traded company. Dr. Quisel led the initiative to re-acquire rights for sotatercept for pulmonary hypertension from Bristol-Myers Squibb, which eventually led to the acquisition of Acceleron by Merck & Co. for over $11 billion in 2021.
0 · Reply
StockScubaDiver
StockScubaDiver Oct. 28 at 7:22 PM
0 · Reply
Zobzork
Zobzork Oct. 28 at 7:15 PM
$GOSS in quebec french, "mes gosses" translates to "my balls" I am investing in my balls 😎
1 · Reply
mdalinaqvi
mdalinaqvi Oct. 28 at 6:01 PM
$GOSS To all the naysayers and detractors, The Phase 2 TORREY trial for Seralutinib was not powered for 6-minute walk distance (6MWD) because its primary endpoint was change in pulmonary vascular resistance (PVR), not 6MWD. Although 6MWD was measured, the trial was not powered to detect statistically significant changes in this metric across the full study population. However, subgroup analysis showed a statistically significant placebo-adjusted improvement of 37 meters in 6MWD among patients classified as WHO Functional Class III. The trial was exploratory and aimed to establish proof-of-concept for Seralutinib’s mechanism. PVR is often considered a more sensitive and direct marker in early-phase PAH trials. ***PROSERA includes nearly 400 patients, with a higher proportion of WHO Functional Class III participants—those most likely to show measurable gains in 6MWD.
1 · Reply
Latest News on GOSS
Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Sep 9, 2025, 9:50 AM EDT - 7 weeks ago

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout


Gossamer Bio to Present at Upcoming Investor Conferences

Aug 29, 2025, 7:31 AM EDT - 2 months ago

Gossamer Bio to Present at Upcoming Investor Conferences


Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 12, 2024, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.


Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Dec 5, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer


Gossamer Bio Announces $212 Million Private Placement Financing

Jul 20, 2023, 7:56 AM EDT - 2 years ago

Gossamer Bio Announces $212 Million Private Placement Financing


Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore

Jan 30, 2023, 4:48 AM EST - 2 years ago

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore


Finnish_boy
Finnish_boy Oct. 31 at 12:29 PM
$GOSS Statistical significance is around 17-18m!! What are the odds that 6mwd is over 20m? I can tell that exteremely high. Lets go!🤑
0 · Reply
Finnish_boy
Finnish_boy Oct. 31 at 12:29 PM
$GOSS "I don't think the investment community has fully yet picked up on that dialogue that's going on in the community." >25m home run 20-25m clinically meaningful 19m already enough for approval What will they show in February, 20m, 25m, or 30m? I like all of them.
1 · Reply
Finnish_boy
Finnish_boy Oct. 28 at 9:58 PM
0 · Reply
mdalinaqvi
mdalinaqvi Oct. 28 at 7:48 PM
$GOSS I am happy with the fact that I have done my thorough due diligence and I entrust my investment in the very capable hands of the management and the board. See you all in Feb 🙏🏻👍
0 · Reply
mdalinaqvi
mdalinaqvi Oct. 28 at 7:33 PM
$GOSS Another fun fact - Mr. Robert Roscigno, PhD (Senior Vice President of Clinical Development, Pulmonary Vascular Disease) Joined Gossamer Bio in July 2020 and has served as Senior Vice President of Clinical Development, Pulmonary Vascular Disease, since September 2024. He is the clinical lead of the Seralutinib program. Dr. Roscigno possesses over 27 years of drug development experience related to pulmonary hypertension and has extensive expertise in developing novel drug/device delivery systems (inhalation, intravenous, subcutaneous) for the pharmaceutical market. He is a co-inventor on multiple U.S. patents and has published numerous articles in scientific journals. Prior to his tenure at Gossamer Bio, Dr. Roscigno held the position of Senior Vice President of Product Development and served as the program lead for LIQ861 (YUTREPIA™) at Liquidia Corporation. He was responsible for advancing the company’s lead product from preclinical testing to NDA submission.
0 · Reply
mdalinaqvi
mdalinaqvi Oct. 28 at 7:27 PM
$GOSS Another fun fact - Mr. Bob Smith - Chief Commercial officer Mr. Smith has over 30 years of experience in pharmaceuticals, with a strong focus on PAH and rare disease. Prior to joining Gossamer, Mr. Smith was the National Sales Lead in charge of preparing for the potential launch of sotatercept for the treatment of PAH in the US at Merck & Co. Mr. Smith spearheaded two successful blockbuster PAH drug launches, OPSUMIT and UPTRAVI, which ultimately led to the purchase of Actelion by Johnson & Johnson in 2017 for $30 billion.
0 · Reply
mdalinaqvi
mdalinaqvi Oct. 28 at 7:24 PM
$GOSS Fun Fact about a Board member of Gossamer Bio - Dr. John Quisel Dr. Quisel is currently the President and CEO of Disc Medicine, a position he has held since January 2020 and during which time, the company established a multi-product portfolio of hematology programs and became a publicly-traded company. Previously, Dr. Quisel was the Executive Vice President and Chief Business Officer at Acceleron Pharma, where he spent more than thirteen years in various senior roles helping to build the company from a privately-held startup to a fully-integrated, publicly-traded company. Dr. Quisel led the initiative to re-acquire rights for sotatercept for pulmonary hypertension from Bristol-Myers Squibb, which eventually led to the acquisition of Acceleron by Merck & Co. for over $11 billion in 2021.
0 · Reply
StockScubaDiver
StockScubaDiver Oct. 28 at 7:22 PM
0 · Reply
Zobzork
Zobzork Oct. 28 at 7:15 PM
$GOSS in quebec french, "mes gosses" translates to "my balls" I am investing in my balls 😎
1 · Reply
mdalinaqvi
mdalinaqvi Oct. 28 at 6:01 PM
$GOSS To all the naysayers and detractors, The Phase 2 TORREY trial for Seralutinib was not powered for 6-minute walk distance (6MWD) because its primary endpoint was change in pulmonary vascular resistance (PVR), not 6MWD. Although 6MWD was measured, the trial was not powered to detect statistically significant changes in this metric across the full study population. However, subgroup analysis showed a statistically significant placebo-adjusted improvement of 37 meters in 6MWD among patients classified as WHO Functional Class III. The trial was exploratory and aimed to establish proof-of-concept for Seralutinib’s mechanism. PVR is often considered a more sensitive and direct marker in early-phase PAH trials. ***PROSERA includes nearly 400 patients, with a higher proportion of WHO Functional Class III participants—those most likely to show measurable gains in 6MWD.
1 · Reply
heyupikachu1821
heyupikachu1821 Oct. 28 at 5:25 PM
$GOSS hard bounce off of 2.3 suggests a new higher low based on previous resistance (neutral to bullish) zooming out to the 1 Month shows a near perfect formation of what could be the first flag in a bull flag pattern (very bullish). would need to see another big move up similar to 10/24 to give that credibility descending back to 2.08 would suggest consolidation (neutral), with support near 2.08 and resistance at 2.5 a break below 2.08, esp a move below 2.0, seems unlikely, but would be very bearish fairly hopeful that we get back to 3.0 to fill the large gap. beyond that, I’d say the 40+% drop from peak suggests the market has deemed 3.5 to be overpriced at the moment, pending any bullish news in terms of successful phase 3 price targets, the 85% drop in response to Phase 2 data suggests you’re really looking at a high of $10 (likely after successful FDA & EMA approval) and I would lean closer to $6.50 as the immediate target activity leading up to phase 3 could change that
1 · Reply
heyupikachu1821
heyupikachu1821 Oct. 27 at 6:28 PM
$GOSS jury is still out on this stock. bounced hard off the support line formed in early August (as expected). momentum of bounce did not continue into the following day (not necessarily a warning sign, but definitely not bullish). and bounce itself was severely delayed (it should have bounced hard last Monday, when it actually hit the August 1 - 4 level - this had me watching very closely as it is a red flag) Seralutinib itself is on very shaky grounds (imo). Phase 3 is always the riskiest obstacle to overcome. but results of Phase 2 were so underwhelming that, even though it succeeded in meeting its primary, the stock dropped 85% in response. this is HIGHLY unusual I’m not sure why so many are very bullish on Phase 3, other than the argument that the market has already priced in a very underwhelming drug compared to its competition what I’ll be watching is how the chart moves from this point forward. do we form a bull flag up? do we resume rising? do we consolidate? or break down?
3 · Reply
SarlaccButtplug
SarlaccButtplug Oct. 27 at 6:00 PM
$GOSS Winrevair got updated. I hope thats good good omen for Gossamer. https://www.merck.com/news/u-s-fda-approves-updated-indication-for-winrevair-sotatercept-csrk-in-adults-with-pulmonary-arterial-hypertension-pah-who-group-1-pulmonary-hypertension-based-on-phase-3-zenith-study/
0 · Reply
AdiDasRom
AdiDasRom Oct. 27 at 3:53 PM
0 · Reply
Zobzork
Zobzork Oct. 27 at 2:05 PM
$GOSS are we back? Is the ride down over? Glad I got back in wednesday @ 2,21 😇
0 · Reply
tink249
tink249 Oct. 27 at 12:24 AM
0 · Reply
Lancealot50
Lancealot50 Oct. 26 at 3:33 PM
$GOSS The orphan drug designation for Gossamer Bio's seralutinib certainly increases its probability of FDA approval compared to drugs without the designation, but it is not a guarantee. The approval will ultimately depend on the drug's performance in its clinical trials, especially the ongoing Phase 3 study. 2. Seralutinib's Specific Clinical Stage The likelihood of approval for seralutinib is heavily dependent on the results of its Phase 3 PROSERA study for Pulmonary Arterial Hypertension (PAH). Phase 3 Success Rate: Drugs that enter Phase 3 trials generally have a reasonable chance of eventually being approved. According to some analytics, the Phase 3 to Pre-Registration transition success rate for PAH drugs is around 67%. Phase 3 PROSERA study with orphan drug designation is from the Phase 2 TORREY trial, which supported the decision to proceed with the pivotal Phase 3 study, with the need for the condition, making approval more likely than for an average non-orphan drug
0 · Reply
BioTechHealthX
BioTechHealthX Oct. 26 at 8:15 AM
$GOSS Gossamer Bio advances a Phase 3 drug that could redefine pulmonary hypertension treatment. See the full story here! https://biotechhealthx.com/biotech-news/gossamer-bio-goss-targets-7-billion-pah-market/
0 · Reply
BigErvy
BigErvy Oct. 26 at 12:40 AM
$GOSS I guess from the negative responses I got the bulls didn't do much dd..instead of giving a reason for being a bull they attacked the messenger with lies.
3 · Reply
redbeamgold
redbeamgold Oct. 25 at 6:42 PM
$GOSS this will keep stepping down till next year.
1 · Reply
BigErvy
BigErvy Oct. 25 at 1:53 PM
$GOSS I don't get why anyone would buy this. I doubt they looked at how many dropped out of their trial.
3 · Reply
Bullsarmy
Bullsarmy Oct. 25 at 8:49 AM
0 · Reply